• ADVANCE-ON demonstrates that intensive glucose control based on gliclazide MR (Diamicron MR) in patients with type 2 diabetes leads to persistent reductions in renal failure, 5.5 years after return to usual care, and without any increase or decrease in the risks of death or cardiovascular disease.
• As end-stage renal disease (ESRD) is a hard renal endpoint, the benefits in reducing ESRD observed in ADVANCE-ON are clinically significant.
• Use of this more intensive glucose-lowering regimen provides substantial benefits in terms of renal protection without jeopardising cardiac safety.